Introduction
============

The World Health Organization (WHO) estimates that by 2030 more than 23 million patients affected by cardiovascular diseases (CVDs) -- the leading cause of death globally -- will die annually ([@B58]), while diabetes will become the seventh leading cause of death ([@B59]). In total, the European region has one of the highest mortality rates for adults under the age of 70 years due to a very high prevalence of cardio-metabolic diseases (CMDs) ([@B30]; [@B57]). CMDs comprise a cluster of risk factors that increase susceptibility to developing CVDs, such as atherosclerosis and arterial thrombosis, metabolic syndrome, and type 2 diabetes mellitus, and its related metabolic traits. CMD-associated risk factors among others include obesity, hypertension, low high-density lipoprotein cholesterol, insulin resistance, glucose intolerance, and elevated triglycerides ([@B17]; [@B8]; [@B54]; [@B7]). Recently, the prevalence of obese individuals with metabolic syndrome in a large cohort of participants across Europe was estimated to reach as high as 78 and 65% in males and females, respectively ([@B52]). Another example is a trend toward the increase in CVD prevalence in certain ethnic groups in Eastern Europe and Western Asia compared to Western Europe (**Figure [1](#F1){ref-type="fig"}**) ([@B1]; [@B56]).

![**Map of Europe and Western Asia showing the distribution of cardiovascular mortality rates in males **(A)** and females (B)**, adapted from the World Health Organization ([@B56]) (age standardized, per 100 000).](fgene-08-00007-g001){#F1}

The uncoupling protein-1 (*UCP1*) gene is located in chromosome 4 of the human genome and is considered to be involved in the pathogenesis of CMDs due to its major role in thermogenesis and energy metabolism ([@B16]; [@B31]). UCP1 is mainly expressed in brown adipose tissue (BAT) and is located in the inner mitochondrial membrane where it catalyzes proton leaks across the membrane, and thus uncoupling oxidative phosphorylation from ATP production ([@B48]). This is proposed to lead to energy dissipation in the form of heat, accompanied by an increase in energy expenditure ([@B60]). It has been suggested that BAT activity, mediated by UCP1 expression, in humans can contribute to 5% of the basal metabolic rate ([@B50]), indicative of a regulatory role of BAT in energy balance and hence body weight. In adult humans, the levels of UCP1 in BAT are diminished with age and are negatively correlated to adiposity ([@B42]; [@B51]). Indeed, individuals with low levels of BAT activity are more susceptible to developing CMDs ([@B31]) and, as we previously proposed, the rate of aging is determined, at least in part, through changes in BAT activity ([@B4]; [@B11]). In addition to age- and adiposity-associated loss of BAT activity, *UCP1* gene variants may also increase one's tendency for developing CMDs by disrupting regular BAT function ([@B25]). In this light, BAT activation is impaired in healthy individuals carrying specific *UCP1* gene variants ([@B33]), corroborating a role of *UCP1* gene variation in adverse metabolic processes and susceptibility to CMDs. Experimental animal evidence supports a relationship between BAT activity and energy homeostasis. For instance, inactivation of *UCP1* due to thermoneutral conditions led to obesity in mice fed both a control diet and high-fat diet, indicating a role of BAT in maintaining a non-obese phenotype ([@B10]). On the other hand, overexpression of *UCP1* in white adipose tissue and skeletal muscle of mice, provided protection against diet-induced obesity, increased energy expenditure, and improved glucose homeostasis ([@B26]; [@B38]). In addition, embryonic BAT transplants have been shown to reverse type 1 diabetes in mice in an insulin receptor activity-dependent mechanism suggesting an important role of BAT in whole-body metabolism ([@B18]).

The current NCBI database of genetic variations shows more than 2300 single nucleotide polymorphisms (SNPs) associated with the *UCP1* gene ([@B43]). The intron--exon structure of the *UCP1* gene is illustrated in **Figure [2](#F2){ref-type="fig"}**. Several studies have investigated the prevalence of such *UCP1* gene variants and their influence on the susceptibility to CMDs, though data still remain scarce among different ethnic groups in Europe. Indeed frequencies for most *UCP1* gene variants have been estimated in selective ethnic groups with small number of participants, rarely reaching more than a few hundreds. Further, the available studies have focused on certain polymorphisms -3826A/G, -112A/C, and -1766A/G in the 5′-region, Ala64Thr in exon 2, and Met229Leu in exon 5 of the gene (reviewed in [@B25]; [@B2]). In addition, emerging evidence of CVD prevalence rates being the highest globally among ethnic groups in Eastern Europe and Western Asia ([@B1]), suggests investigation of the effect of *UCP1* gene variants on CMD predisposition across these regions. Therefore, accurate estimation of the prevalence of the most commonly studied *UCP1* gene variants and identification of ethnic groups at high risk of developing CMDs warrants further analysis in large cohorts of patients and healthy controls. Integration of the findings to national public health policies may substantially improve CMD preventive and management strategies.

![**Intron--exon structure of the *UCP1* gene is shown (green blocks) according to two predicted transcripts (XM_005263206.2 and XM_011532228.1 with corresponding protein forms XP_005263263.1 and XP_011530530.1).** Protein coding regions are shown by orange blocks, coding sequence of *UCP1* gene is in reverse chromosome DNA strand. Position of XM_005263206.2 in genome is indicated (140,559,394 ... 140,568,902 bp). Seven mostly investigated variants of the UCP1 gene are located on the map: -3826A/G (rs1800592), -3737C/A (rs7687015), -1766A/G (rs3811791), -412A/C (rs3811787), -112A/C (rs10011540), Arg64Thr (rs45539933), Met229Leu (rs2270565). Distribution of known genetic variants along the locus is shown at the bottom (blue bars).](fgene-08-00007-g002){#F2}

The Hypothesis of the *UCP1* Genetic Variation Effect on the Interethnic Differences in CMD Prevalence Rates
============================================================================================================

On the grounds of experimental evidence corroborating an association of *UCP1* gene variants and CMDs, we hypothesize that the ethnic-specific predisposition to CMDs could be attributed, at least partially, to the diverse prevalence of specific *UCP1* gene variants among different ethnic groups. Such an increased susceptibility to the development of CMDs has been observed specifically in ethnic groups in Eastern Europe and Western Asia (**Figure [1](#F1){ref-type="fig"}**). Large population-based studies are thus required to investigate the CMD-related association of specific *UCP1* gene variants among different ethnic groups. Information on ethnic-specific genotypes' frequencies of the analyzed *UCP1* gene variants could be used to identify those ethnic groups at high-risk of developing CMDs, and further explain to an extent the high CMD prevalence rates observed in Eastern Europe and Western Asia.

Evaluation of the Ethnic-Specific *UCP1* Gene Variants in CMD Susceptibility and Prevalence Rates
-------------------------------------------------------------------------------------------------

Due to its aforementioned role in the regulation of energy metabolism, UCP1 has been considered a potential genetic risk factor for predisposition to CMDs ([@B10]; [@B25]). For that reason, numerous genetic association studies in selective European populations have been performed to explore a potential link between *UCP1* gene variants and CMDs, often yielding to controversial results. A number of independent genetic association studies suggested an association between *UCP1* gene variants and obesity, type 2 diabetes mellitus, body fat distribution, and metabolic syndrome-related traits ([@B6]; [@B19]; [@B27]; [@B13]; [@B21]; [@B40]; [@B46]), while other studies failed to demonstrate such correlations ([@B49]; [@B12]; [@B14]; [@B44]; [@B36]; [@B29]; [@B32]). The most commonly studied *UCP1* gene variant is -3826A/G, while the synergistic effect of several variants in *UCP1* gene has been investigated to a lesser extent (reviewed in [@B2]). To our knowledge, there has been no genetic association study to investigate the combined effect of the most common *UCP1* gene variants on the susceptibility to CMDs among different ethnic groups in Europe.

On the other hand, differences in the number of UPC1 polymorphism carriers have been reported in various populations ([@B25]). However, given the relatively low prevalence of UCP1 gene polymorphisms \[can be as low as 2 or 6% for specific polymorphisms ([@B53])\], these data are limited by the small sample sizes assessed (\<500 participants) ([@B28]; [@B20]; [@B34]). Small study populations limit the accuracy of genotype prevalence estimates (e.g., only 10 identified individuals in a study of 200 participants with a 5% UCP1 gene polymorphism prevalence rate), making it difficult to integrate the evidence and, thus, to easily translate the findings into public health improvements ([@B24]; [@B5]). More recent studies investigating the prevalence of genetic polymorphisms and their impact on health and disease included thousands of participants among diverse populations ([@B61]). Given also the increased CMD prevalence rates specifically in ethnic groups in Eastern Europe and Western Asia, it is expected that large case-control, population-based studies will identify those *UCP1* gene variants that predispose ethnic groups across these regions to CMD development. Despite their increased cost, such studies will potentially explain the highest CMD prevalence rates observed across these regions at a global level.

Further studies to investigate a synergistic effect of the studied *UCP1* gene variants with environmental (geographical location, climate, diet, and physical activity) and/or socio-economic (education, income, and cultural conception) factors could significantly contribute to define the association between the genetic variation in *UCP1* gene and CMDs, by fully adjusting for such potential confounders. The emerging field of human social genomics highlights the importance of the contemporary dynamic social adverse conditions on influencing ones genotype and hence further shaping the susceptibility to chronic diseases. On the other hand, gene variants can also alter genotypic response to socio-environmental adversities by activating different molecular pathways and factors, and thus enhancing or reducing the risk for chronic disease ([@B45]). Future investigation to address such dynamic effects of external social environment on *UCP1* gene expression may also reveal additional factors, such as experience of chronic social isolation and isolation of obese individuals, which could in turn either enhance or reduce the impact of specific *UCP1* gene variants on ethnic-specific predisposition to CMDs.

We propose to investigate the putative association of the several *UCP1* gene variants with the development of CMDs. All patients and volunteers in this study will derive from six different ethnic groups, with ethnicity to be defined by self-report. Our sample population will be comprised of 1500 unrelated individuals aged of \>18 years diagnosed with type-2 diabetes, obesity, and metabolic syndrome with or without hypertension. Our control group will contain 1500 age- and gender-matched healthy individuals. Exclusion criteria will include individuals \< 18 years of age, smoking, history of eating disorder, pregnancy or lactation, acute illness and/or infection (last 4 weeks). Participants will be white Caucasians of European and Western Asian origin. They will be weighed, their height will be measured, and their BMI will be calculated. Blood pressure will be assessed. Percent body fat will be measured three times, and waist-to-hip ratio will be calculated. Further, after an overnight fast, plasma glucose will be measured. Environmental and socio-economic factors will be determined by using standardized questionnaires. The seven most commonly studied *UCP1* gene variants (**Figure [2](#F2){ref-type="fig"}**) will be genotyped. Genomic DNA will be extracted from whole blood and each *UCP1* gene variant will be assessed by Real Time Taqman method. To our knowledge only three studies have conducted *in vitro* or *in vivo* studies to characterize the function of two specific *UCP1* gene variants (rs1800592 and rs7687015) ([@B9]; [@B41]; [@B2]). We aim, therefore, to assess the putative functional relevance of specific alleles and haplotypes of the aforementioned variants on the transcriptional activity of *UCP1* by *in vitro* reporter assays. Appropriate statistical analysis will be used to investigate the associations of *UCP1* variant-specific alleles and haplotypes with CMDs, and in relation with clinical characteristics. The modifying effect of environmental factors, with a special focus on diet variation among the different ethnic groups studied, on the association between CMDs and UCP1 gene variants will also be examined. Further, the effect of socio-economic factors on *UCP1* transcriptional activity as putatively mediated by the analyzed alleles and haplotypes of *UCP1* gene variants will also be determined.

This proposed investigation of the combined effect of the most commonly studied *UCP1* gene variants on CMD prevalence in a very large and ethnically diverse sample of patients and healthy individuals will identify high-risk ethnic groups for developing CMDs. Further, the study of *UCP1* gene variants-environment interactions will define a strong association between *UCP1* gene variants and CMD development.

Assessment of the Clinical Implications and the Impact of *UCP1* Gene Variants on Public Health Care System, Policy and Preventive Practices
============================================================================================================================================

Cardio-metabolic diseases constitute a serious public health concern with a substantial impact not only on life expectancy ([@B3]; [@B39]; [@B56], [@B57]; [@B8]; [@B7]) but also on healthcare services at a major cost to the economy ([@B55]). A substantial economic pressure on healthcare systems is imposed by CVDs across Europe, reaching €196 billion per year ([@B35]). Recent reports predict a 33% increase in the global market for drugs treating CVDs from 2012 to 2019 ([@B15]). Further, USA comprise the biggest single market for anti-obesity drugs, with around 68% of the population either overweight or obese, followed by the UK and other European countries ([@B22]).

Despite the growing cost of anti-CMD agents, there is concern that the drugs fail to provide lasting benefits for health and well-being ([@B23]). In this light, identification of interethnic differences in *UCP1* gene variants that could predispose certain ethnic groups to the development of CMDs could assist in the design of effective preventive and management practices, with beneficial outcomes for the public health care services. *UCP1* gene variants have been associated with high levels of low-density lipoprotein (LDL) cholesterol and diastolic blood pressure, as well as with low levels of high-density lipoprotein (HDL) cholesterol ([@B27]; [@B37]). In turn, high levels of circulating LDL cholesterol are implicated in the development of atherosclerosis and represent important pharmacological target in preventing the progression of atherosclerosis and event of coronary heart disease and stroke ([@B47]). Therefore, it is evident that a fresh perspective in targeted interventions is necessary to efficiently manage the massive projected increase of CMDs over the next decades.

The diverse distribution of CMDs among different ethnic groups could be also attributed to environmental factors, and socio-economic factors. WHO estimates that more than 80% of CVDs and diabetes deaths occur in low-and middle-income countries ([@B58],[@B59]). It is therefore crucial to determine the potential modifying effects of the environmental factors on the *UCP1* gene variation risk pattern of CMD development. Lastly, in light of a growing body of evidence, the once accepted conception on an otherwise stable and impermeable genetic make-up has been challenged, supporting reciprocal gene-adverse social environment interactions, with putative strong impact on the role of certain UCP1 gene variants in defining ethnic-specific susceptibility to CMDs.

Conclusion
==========

The association between specific *UCP1* gene variants and CMDs has been investigated in certain ethnic groups, often leading to controversial results. There is the need to improve our understanding on the prevalence of the most commonly studied *UCP1* gene variants among various ethnic groups and their impact on the predisposition to CMDs. It can be hypothesized that interethnic differences in the distribution of *UCP1* gene variants could account, at least in part, for such a diverse population-specific predisposition to CMDs. One such example of a wide variation in CMD prevalence rates has been observed across Europe and Western Asia. Addressing this hypothesis in multi-ethnic based studies will provide information on the functional effect of these genetic variants on the pathogenetic mechanisms of CMDs. Identifying high-risk ethnic groups of developing CMDs will set the ground for defining public health policies and improving existing preventive and management strategies.
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